Nicox: Bryan Garnier raises target price

(CercleFinance.com) - Bryan Garnier has confirmed its "buy" rating on the Nicox stock and has raised its fair value from 14.
3 euros to 17 euros, highlighting the group's "shift in the centre of gravity" to the United States, having received two approvals from the FDA.

“We expect visibility to further increase in 2018 with: 1/ the first sales of recently launched Vyzulta (glaucoma) by Valeant and 2/ the upcoming launch of Zerviate (allergic conjunctivitis) by US-based partner, Eyevance,” the broker explains.

The broker adds that increased royalties should help support a steady pace of innovation and reduce the risks of the ophthalmic company's pipeline.


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.